Anti-obsessional and antidepressant profile of besipirdine

CNS Drug Reviews

Volumn 3, Issue 1, 1997, Pages 1-23

  Smith, C P ^a   Woods Kettelberger, A T ^a   Corbett, R ^a   Porsolt, R D ^b   Roehr, J E ^a   Bores, G M ^a   Giovanni, A ^a   Szewczak, M R ^a   Rush, D K ^a   Martin, L L ^a   Klein, J T ^a   Turk, D J ^a   DiLeo, E M ^a   Effland, R C ^a   Huger, F P ^a   Kongsamut, S ^a  

^a SANOFI   (France)

^b ITEM Labo   (France)

Author keywords

HP 749 Obsessive compulsive disorder (OCD); P7480; Schedule induced polydipsia (SIP)

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ATROPINE; BESIPIRDINE; CARBACHOL; CHOLINERGIC RECEPTOR STIMULATING AGENT; CLOMIPRAMINE; DEPROPYLBESIPIRDINE; DESIPRAMINE; DOXEPIN; FLUOXETINE; IDAZOXAN; IMIPRAMINE; IPRINDOLE; MIANSERIN; OXOTREMORINE; TRAZODONE; UNCLASSIFIED DRUG; ZIMELDINE;

ANIMAL BEHAVIOR; DEPRESSION; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG SCREENING; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; OBSESSION; POLYDIPSIA; REVIEW;

EID: 12644311285     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1997.tb00313.x     Document Type: Review

References (103)

1. Aronstam RS, Narayanan TK. Temperature effect on the detection of muscarinic receptor-G protein interactions in ligand binding assays. Biochem Pharmacol 1988;37:1045-1049.
2. Auerbach SB, Lundberg JF, Hjorth S. Differential inhibition of serotonin release by 5-HT and NA reuptake blockers after systemic administration. Neuropharmacology 1995;34:89-96.
3. Avorn J, Everitt DE, Weiss S. Increased antidepressant use in patients prescribed β-blockers. JAMA 1986;255:357-360.
4. Baraban JM, Aghajanian GK. Suppression of firing activity of 5-HT neurons in the dorsal raphé by alpha-adrenoceptor antagonists. Neuropharmacology 1980;19:355-363.
5. Benesova O, Nahurek H. Correlation between the experimental data from animal studies and therapeutical effects of antidepressant drugs. Psychopharmacology 1971;20:337-347.
6. Benfield DP, Harries CM, Luscombe DK. Some pharmacological aspects of desmethylclomipramine. Postgrad Med J (Suppl 1) 1980;56:13-18.
7. Bhargava VK, Salamy A, McKean CM. Effect of cholinergic drugs on the brainstem auditory evoked responses (far-field) in the rat. Neuroscience 1978;3:821-826.
8. Birdsall NJM, Burgen ASV, Hulme EC. The binding of agonists to brain muscarinic receptors. Mol Pharmacol 1978;14:723-736.
9. Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 1995;15:217-222.
10. Borsini P, Meli A. Review: Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology 1988;94:147-160.
11. Boxenbaum H. Interspecies scaling, allometry, physiological time and the ground plan for pharmacokinetics. J Pharmacokinet Biopharm 1982;10:201-227.
12. Byerley WF, McConnell EJ, McCabe RT, Dawson TM, Grosser BI, Wamsley JK. Decreased beta-adrenergic receptors in the rat brain after chronic administration of the selective serotonin uptake inhibitor fluoxetine. Psychopharmacology 1988;94:141-143.
13. 2-Adrenoceptor antagonists potentiate acetylcholines-terase inhibitor effects on passive avoidance learning in the rat. Psychopharmacology 1996;124:347-354.
14. + channels: local anesthetics, antiarrythmics, and anticonvulsants. Trends in Pharmaceutical Sci 1987;8:57-65.
15. Cesana R, Ceci A, Ciprandi P, Borsini F. Mesulergine antagonism towards the fluoxetine anti-immobility effect in the forced swimming test in mice. J Pharm Pharmacol 1993;45:473-475.
16. Chan-Palay V. Depression and senile dementia of the Alzheimer type: Catecholamine changes in the locus coeruleus - basis for therapy.- Dementia 1990,1:253-261.
17. Chesson SM, Mutlib AE. In vitro and in vivo metabolism of besipirdine (HP 749) in dogs, rats and humans. ISSX Proceedings 1995;8:51.
18. Cornfeldt M, Fisher B, Fielding S. Rat internal capsule lesion: A new test for detecting antidepressants. Fed Proc 1982;41:1066.
19. Cornfeldt M, Wirtz-Brugger P, Szewczak MR, et al. HP 749 (1). A pharmacological profile of a therapeutic agent for Alzheimer's disease. Soc Neurosci Abstr 1990;16:612.
20. Cuadra G, Giacobini E. Coadministration of cholinesterase inhibitors and idazoxan: Effects of neuro-transmitters in rat cortex in vivo. J Pharmacol Exp Ther 1995;273:230-240.
21. Davis KL, Thal LJ, Gamzu ER, et al. A double-blind, placebo-controlled, multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992;327:1253-1259.
22. 2-adrenoceptor antagonist Org 3770 enhances serotonin transmission in vivo. Eur J Pharmacol 1994;253:R5-R6.
23. 2 adrenoceptors play a major role in the effects of idazoxan on cortical noradrenaline release (as measured by in vivo dialysis) in the rat. J Pharmacol Exp Ther 1987;241:642-649.
24. DiLeo EM, Hsu RS, Chesson SM, Linville AR, Klein JT, Effland RC. Metabolism and elimination of HP 749 in the rat, dog, and man. Pharmaceutical Res 1991;8:S237.
25. Effland RC, Klein JT, Davis KL, Olsen GE. N-(Pyridinyl)-1H-indol-1-amines. U.S. Patent #4,970,218; 1990.
26. Eilam D, Szechtman H. Towards an animal model of obsessive-compulsive disorder (OCD): Sensitization to dopamine agonist quinpirole. Soc Neurosci Abstr 1995;21:192.
27. Eison AS, Eison MS, Torrente JR, Wright RN, Yocca FD. Nefazodone: Preclinical pharmacology of a new antidepressant. Pyschopharmacol Bull 1990;26:311-315.
28. Feighner JP, Pambakian R, Fowler RC, Boyer WR, D'Amico MF. A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression. Pyschopharmacol Bull 1989;25:219-221.
29. Francis EZ, Kimmel CA, Rees DC. Workshop on the qualitative and quantitative comparability of human and animal developmental neurotoxicity: Summary and implications. Neurotoxicol Teratol 1990;12:285-292.
30. Garratt JC, Crespi F, Mason R, Marsden CA. Effects of idazoxan on dorsal raphé 5-hydroxytryptamine neuronal function. Eur J Pharmacol 1991;193:87.
31. 2-adrenoceptor antagonist with serotonin uptake-blocking activity and putative antidepressant-like effects: II. Pharmacology profile. Drug Dev Res 1995;35:246-260.
32. Giovanni AG, Bores GM, Li M, et al. Combined cholinergic and adrenergic candidates for Alzheimer's Disease therapy (II): In vivo biochemical activity. Soc Neurosci Abstr 1995;21:1975.
33. Goodman WK, Price LH, Delgado DL, et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1990;47:577-585.
34. Grahame-Smith DG. Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with monoamine oxidase inhibitors and L-tryptophan. J Neurochem 1971;18:1053-1066.
35. 2-adrenergic receptors and inhibits the neuronal uptake of norepinephrine. J Pharmacol Exp Ther 1995;272:1160-1169.
36. Henderson AS. Co-occurrence of affective and cognitive symptoms: The epidemiological evidence. Dementia 1990;1:119-123.
37. 1A autoreceptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo: A microdialysis study. J Neurochem 1993;60:776-779.
38. 1A autoreceptor blockade in the citalopram plus WAY100635-induced elevation of extracellular 5-HT in the rat brain in vivo. Soc Neurosci Abstr 1996;22:1326.
39. Hsu RS, Hubbard JW, Chesson SM, DiLeo EM, Effland RC, Klein JT. Determination of HP 749, a potential therapeutic agent for Alzheimer's disease in plasma by high-performance liquid chromatography. J Chromat 1991;572:352.
40. Hubbard JW, Hsu RS, Griffiths L, et al. The pharmacokinetics and cardiovascular pharmacodynamics of HP 749 (besipirdine HCl) and metabolite P86-7480 in the conscious monkey. J Clin Pharmacol 1995;35:688-696.
41. 2-Adrenergic activity and cardiovascular effects of besipirdine (HP 749) and metabolite P86-7480 in vitro and in the conscious rat and dog. J Phannacol Exp Ther 1997 (in press).
42. Huff FJ, Anttuono PG, Delagandara JE, et al. A treatment and withdrawal trial of besipirdine in Alzheimer disease. Akheimer Disease and Associated Disorders 1996;10:93-102.
43. Huger FP, Smith CP. Receptor binding assays for muscarinic cholinergic agonists. In: O'Brien RA, ed. Receptor Binding in Drug Research. New York and Basel: Marcel Dekker, Inc. 1986:497-510.
44. Huger FP, Smith CP, Petko WW, Conway PC, Effland RC, Klein JT. HP 749. A potential therapeutic agent for Alzheimer's disease: II. Neurochemical profile. Soc Neurosci Abstr 1990;16:612.
45. Huger FP, Kongsamut S, Smith CP, Tang L. Use of unsubstituted and substituted N-(pyrrol-1-yl)pyridinamines as anticonvulsant agents. Patent submitted July 1995.
46. Insel TR, Zohar J, Benkelfat C, Murphy D. Serotonin in obsessions, compulsions and the control of aggressive impulses. Ann NY Acad Sci 1990;600:574-586.
47. Insel TR, Zohar J, Benkelfat C, Murphy DL. Serotonin in obsessions, compulsions, and the control of aggressive impulses. Ann NY Acad Sci 1991;600:574-586.
48. Jaslove SW. Six month efficacy and safety study of besipirdine hydrochloride (HP 749) in patients with Alzheimer's disease - end of double-blind treatment report. Internal Clinical Study Report HP 749/USA/301/DZ 1995; Clinical Neuroscience Section, Hoechst-Roussel Pharmaceuticals, Inc.
49. Jacobs BL. An animal behavioral model for studying central serotoninergic synapses. Life Sci 1976;19:777-786.
50. Jenike MA, Hyman S, Baer L, et al. A controlled trial of fluvoxamine in obsessive-compulsive disorder: Implications for a serotonergic theory. Am J Psychiatry 1990;147:1209-1215.
51. Kawashima K, Araki H, Aihara H. Effect of chronic administration of antidepressants on duration of immobility in rats forced to swim. Jpn J Pharmacol 1986;40:199-204.
52. Klein JT, Davis L, Olsen GE, et al. Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine) (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's Disease. J Med Chem 1996;39:570-581.
53. Kongsamut S, Smith CP, Woods AT. Use of N-(pyridinyl)-1H-indol-1-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders. European Patent #94110875.5. September 6, 1994.
54. Kongsamut S, Smith CP, Woods AT. Use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive compulsive disorder. U.S. Patent #5,356,910. October 18, 1994.
55. Laakmann G, Gugarth M, Kuss HJ, Zygan K. Comparison of growth hormone and prolactin stimulation induced by chlorimipramine and desimipramine in man in connection with chlorimipramine metabolism. Psychopharmacology 1984;82:62-67.
56. Leonard HL, Swedo SE, Rapoport JL, et al. Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents. Arch Gen Psychiatry (Suppl 5) 1989;52:58-62.
57. 2-adrenoceptor agonists and antagonists. Fourth International Nice/Springfield Symposium on Advances in Akheimer Therapy 1996:160.
58. Montgomery SA. Venlafaxine: A new dimension in antidepressant pharmacotherapy. J Clin Psychiatry 1993;54:119-126.
59. Muth EA, Haskins JT, Moye JA, Husbands GEM, Neilsen ST, Sigg ED. Antidepressant biochemical profile of the novel tricyclic compound WY-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986;35:493-97.
60. 125I]lodopindolol to β-adrenoceptors in the amygdala of rat after antidepressant treatments. J Pharmacol Exp Ther 1991;257:681-690.
61. 2-adrenoceptor antagonist and monoamine re-uptake inhibitor. J Pharmacol Exp Ther 1990;254:476-483.
62. Pettibone DJ, Pflueger AB, Totaro JA. Tetrabenazine-induced depletion of brain monoamines: Mechanism by which desmethylimipramine protects cortical norepinephrine. Eur J Pharmacol 1984;102:431-436.
63. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977;229:327-336.
64. 1A agonists: Anxiolytic-like and antidepressant-like effects in three behavioral models. First European Congress Pharmacology, Milan, Italy, June, 1995.
65. Rapoport JL. Recent advances in obsessive-compulsive disorder. Neuropsychopharmacology 1991;5:1-9.
66. Rasmussen SA, Eisen JL. The epidemiology and differential diagnosis of obsessive, compulsive disorder. J Clin Psychiat (Suppl) 1992;53:4-10.
67. Rasmussen SA, Goodman WK, Woods SW, Heninger GR, Charney DS. Effects of yohimbine in obsessive compulsive disorder. Psychopharmacology 1987;93:308-313.
68. Rauch SL, O'Sullivan RL, Jenike MA. Open treatment of obsessive-compulsive disorder with Venlafaxine: A series often cases. J Clin Psychopharmacol 1996;16:81-83.
69. Reifler BV. Mixed cognitive-affective disturbances in the elderly: A new classification. J Clin Psychiatry 1986;47:354-356.
70. Riekkinen P Jr, Sirvio J, Valjakka A, Riekkinen M, Lammintausta R, Riekkinen P. Effects of atipamezole and tetrahydroaminoacridine on nucleus basalis lesion-induced EEC changes. Brain Res Bull 1991;27:231-235.
71. Ritschel WA. In: Handbook of Basic Pharmacokinetics. Hamilton, IL: Drug Intelligence Publications, 1986:316-319.
72. Roehr JE, Woods AT, Corbett R, Kongsamut S. Changes in paroxetine binding in the cerebral cortex of polydipsic rats. Eur J Pharmacol 1995;278:75-78.
73. Rogers SL, Friedhoff LT. Donepezil (E2020) produces long-term clinical improvement in Alzheimer's Disease. Fourth International Nice/Springfield Symposium on Advances in Alzheimer Therapy, 1996:56.
74. Rutter JJ, Gundalah C, Auerbach SB. Systemic uptake inhibition decreases serotonin release via somatodendritic autoreceptor activation. Synapse 1995;20:225-233.
75. Ryan CN, Evenden JL, Petterson M. Effects of buspirone and ipsapirone on schedule induced polydipsia: comparison with 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and ractopride. Psychopharmacology 1993;112:34-44.
76. Santucci AS, Haroutunian V, Davis KL. Pharmacological alleviation of combined cholinergic/noradrenergic lesion-induced memory deficits in rats. Clin Neuropharmacol (Suppl 1) 1991;14:S1-S8.
77. Sarter M, Hagan J, Dudchenko P. Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part 1. Psychopharmacology 1992;107:144-159.
78. Sarter M, Hagan J, Dudchenko P. Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part II. Psychopharmacology 1992;107:461-473.
79. Scinto LF, Daffner KR, Dressier D, et al. A potential noninvasive neurobiological test for Alzheimer's disease. Science 1994;266:1051-1054.
80. Scott JA, Crews FT. Down-regulation of serotonin, but not β-adrenergic receptors during chronic amitriptyline treatment is independent of serotonin and β-adrenergic receptor stimulation. Neuropharmacology 1986;25:1301-1306.
81. Scrip 1995;2032:27.
82. Scrip 1995;2020:23.
83. 3H]QNB displacement by cholinergic agonists and antagonists. Biochem Pharmacol 1983;32:377-380.
84. 3H]norepinephrine release from rat cortical slices by N-(n-propyl)-N-(4-pyridinyl)-1H-indol-1-amine. Drug Dev Res 1994;32:13-18.
85. 3H]norepinephrine from rat cortical slices and synaptosomes. Neurochemical Res 1994;10:1265-1270.
86. Sramek JJ, Viereck CF, Huff J, et al. A bridging (safety/tolerance) study of besipirdine hydrochloride in patients with Alzheimer's Disease. Life Sci 1995;57:1241-1248.
87. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-713.
88. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 1985;85367-370.
89. Steru L, Chermat R, Thierry B, et al. The automated Tail Suspension Test: A computerized device which differentiates psychotropic drugs. Prog Neuropsychopharmacol Exp Psychiatry 1987;11:659-671.
90. Sugrue MF. Chronic antidepressant therapy and associated changes in central monoaminergic receptor functioning. Pharmacol Ther 1983;21:1-33.
91. Sulser F, Vetulani J, Mobley PL. Mode of action of antidepressant drugs. Biochem Pharmacol 1978;27;257-261.
92. Szewczak MR, Fielding S, Cornfeldt M. Rat internal capsule lesion: further characterization of antide-pressant screening potential. Soc Neurosci 1982;8:465.
93. Tang L, Smith CP, Huger FP, Kongsamut S. Effects of besipirdine at the voltage-dependent sodium channel. Br J Pharmacol 1995;116:2468-2472.
94. Tang L, Kongsamut S. Frequency-dependent inhibition of neurotransmitter release by besipirdine and HP 184. Eur J Pliarmacol 1996;300:71-74.
95. 2-adrenoceptor antagonist (+)-efaroxan enhances acetylcholine release in the rat cortex in vivo. Eur J Pharmacol 1995;277:113-116.
96. 3H]Pirenzepine selectively identifies a high affinity population of muscarinic cholinergic receptors in the rat cerebral cortex. Life Sci 1982;31:2019-2023.
97. Weich NL, Ursillo RC. Acceleration of desipramine-induced decrease of rat corticocerebral β-adrenergic receptors by yohimbine. Commun Psychopharmacol 1980;4:95-100.
98. Willow M, Gonoi T, Catterall WA. Voltage clamp analysis of the inhibitory actions of diphenylhydantoin and carbamazepine on voltage-sensitive sodium channels in neuroblastoma cells. Mol Pliarmacol 1985;27:549-558.
99. Woodbury LA, Davenport VP. Design and use of a new electroshock seizure apparatus and analysis of factors altering seizure threshold and pattern. Arch Int Pharmacodyn 1952;92:97-197.
100. Woods A, Smith CP, Szcwczak MR, Dunn RW, Cornfeldt M, Corbett R. Selective serotonin reuptake inhibitors decrease schedule-induced polydipsia in rats: A potential model for obsessive compulsive disorder. Psychopharmacology 1993;112:195-198.
101. Woods-Kettelberger AT, Smith CP, Corbett R. Besipirdine (HP 749) reduces schedule-induced polydipsia in rats. Brain Res Bull 1996;41:125-130.
102. Wragg RE, Jeste DV. Depression and psychosis in Alzheimer's disease. Am J Psychiatry 1989;146:577-587.
103. Zaczek R, Tinker WJ, Logue AR, Cain GA, Teleha CA, Tam SW. Effects of linopitidine, HP 749, and glycyl-prolyl-glutamate on transmitter release and uptake. Drug Dev Res 1993;29:203-208.